[1] |
Yu J, Sheng Z, Wu S, et al. Tumor DNA from tumor in situ fluid reveals mutation landscape of minimal residual disease after glioma surgery and risk of early recurrence[J]. Front Oncol, 2021, 11: 742037. DOI: 10.3389/fonc.2021.742037.
|
[2] |
李锋, 王国辉, 常晓静, 等. 高级别脑胶质瘤术后同步加量与序贯加量调强放疗疗效比较[J]. 中华放射肿瘤学杂志, 2022, 31(6): 513-518. DOI: 10.3760/cma.j.cn113030-20210823-00317.
|
[3] |
Piotrowski AF, Jackson S. Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: moving forward by looking back[J]. Neuro Oncol, 2022, 24(8): 1387-1388. DOI: 10.1093/neuonc/noac081.
|
[4] |
Luo C, Luo Q, Xu Y, et al. Analysis of clinical characteristics and risk factors of postoperative recurrence and malignant transformation of low-grade glioma[J]. J Oncol, 2022, 2022: 4948943. DOI: 10.1155/2022/4948943.
|
[5] |
《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J]. 中华医学杂志, 2016, 96(7): 485-509. DOI: 10.3760/cma.j.issn.0376-2491.2016.07.003.
|
[6] |
Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with cancer: JACC: cardiooncology state-of-the-art review[J]. JACC: Cardiooncology, 2021, 3(2): 173-190. DOI: 10.1016/j.jaccao.2021.03.001.
|
[7] |
林艺, 王策, 康勋, 等. 胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析[J]. 中国癌症杂志, 2022, 32(1): 13-23. DOI: 10.19401/j.cnki.1007-3639.2022.01.002.
|
[8] |
Zheng H, Yan TN, Han YS, et al. Nomograms for prognostic risk assessment in glioblastoma multiforme: applications and limitations[J]. Clin Genet, 2022, 102(5): 359-368. DOI: 10.1111/cge.14200.
|
[9] |
Huang RH, Wang TW, Liao ZJ, et al. A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma[J]. Ann Palliat Med, 2021, 10(5): 5391-5399. DOI: 10.21037/apm-21-823.
|
[10] |
Teng CB, Zhu YW, Li YS, et al. Recurrence- and malignant progression-associated biomarkers in low-grade gliomas and their roles in immunotherapy[J]. Front Immunol, 2022, 13: 899710. DOI: 10.3389/fimmu.2022.899710.
|
[11] |
孟凡萱, 崔久嵬. 血小板:肿瘤诊断与治疗的新兴靶点[J]. 中国肿瘤生物治疗杂志, 2023, 30(1): 10-19. DOI: 10.3872/j.issn.1007-385x.2023.01.002.
|
[12] |
Wojtukiewicz MZ, Sierko E, Hempel D, et al. Platelets and cancer angiogenesis nexus[J]. Cancer Metastasis Rev, 2017, 36(2): 249-262. DOI: 10.1007/s10555-017-9673-1.
|
[13] |
Xu WP, Xu HH, Fang MM, et al. MKL1 links epigenetic acti-vation of MMP2 to ovarian cancer cell migration and invasion[J]. Biochem Biophys Res Commun, 2017, 487(3): 500-508. DOI: 10.1016/j.bbrc.2017.04.006.
|
[14] |
Sol N, Wurdinger T. Platelet RNA signatures for the detection of cancer[J]. Cancer Metastasis Rev, 2017, 36(2): 263-272. DOI: 10.1007/s10555-017-9674-0.
|
[15] |
Dincel O, Bayraktar C. Evaluation of platelet indices as a useful marker in papillary thyroid carcinoma[J]. Bratisl Lek Listy, 2017, 118(3): 153-155. DOI: 10.4149/BLL_2017_030.
pmid: 28319410
|
[16] |
Wang X, Cui MM, Xu YY, et al. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer[J]. Oncotarget, 2017, 8(40): 68115-68122. DOI: 10.18632/oncotarget.19242.
pmid: 28978101
|